

27th August, 2014

Mr. Rajendra Bhosale
(Assistant Manager)
National Stock Exchange of India Ltd.,
Exchange Plaza,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Clarification on news item appearing in Business Standard on 26-Aug-14

This is with reference to your email dated 26-Aug-14 seeking clarification on news item appearing in Business Standard on 26-Aug-14 captioned "**Torrent Pharma gets price exemption for new drug**".


In this regard, we would like to inform that the Company has received an exemption from the applicability of the provisions of Drugs Price Control Order, 2013 (DPCO) for a newly developed fixed dosed combination of Prasugrel Hydrochloride and Aspirin. The exemption is for a period of five years under para 32 of the DPCO.

We would also further inform that the impact of this exemption is not material.

Kindly take note of the above.

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY